Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immunic said four abstracts on vidofludimus calcium were accepted for presentation at the MSToronto2026 multiple sclerosis meeting in Toronto later this month. The company also cited new Phase 2 CALLIPER open-label extension data and exploratory biomarker and preclinical findings.
Immunic flagged new Phase 2 CALLIPER open-label extension results for vidofludimus calcium in progressive multiple sclerosis, with low discontinuation rates through week 48; data to be presented Oct. 21-23 at MSToronto2026.
Immunic said four accepted abstracts on vidofludimus calcium will be presented at the October 21-23 MSToronto2026 meeting in Toronto. The company also highlighted new CALLIPER open-label extension data and preclinical and biomarker findings in multiple sclerosis.